Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors | Zendy

Elizabeth Fox | Zendy; Brigitte C. Widemann | Zendy; Devang Pastakia | Zendy; Clara C. Chen | Zendy; Sherry Yang | Zendy; Diane E. Cole | Zendy; Frank M. Balis | Zendy

Open Access

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

Author(s) -

Elizabeth Fox,

Brigitte C. Widemann,

Devang Pastakia,

Clara C. Chen,

Sherry Yang,

Diane E. Cole,

Frank M. Balis

Publication year - 2015

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-015-2845-1

Subject(s) - docetaxel , vinorelbine , pharmacology , medicine , pharmacodynamics , pharmacokinetics , doxorubicin , chemotherapy , cisplatin

P-glycoprotein (Pgp), an ATP-dependent transport protein, confers multidrug resistance in cancer cells. Tariquidar binds and inhibits Pgp. To assess the toxicity, pharmacokinetics (PK), and pharmacodynamics of tariquidar, we conducted a phase I trial of tariquidar in combination with doxorubicin, docetaxel, or vinorelbine in children and adolescents with recurrent or refractory solid tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research